Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation.

Br J Haematol · 2025 · PMC11739750 · PMID 39622271

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

15.1 months; HR: 0.78; 95% CI, 0.62–0.98; p = 0.032) and showed a trend towards improved OS when censoring for allo‐HSCT (HR: 0.75; 95% CI, 0.56–1.01).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.